HUP0303719A2 - Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra - Google Patents
Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukraInfo
- Publication number
- HUP0303719A2 HUP0303719A2 HU0303719A HUP0303719A HUP0303719A2 HU P0303719 A2 HUP0303719 A2 HU P0303719A2 HU 0303719 A HU0303719 A HU 0303719A HU P0303719 A HUP0303719 A HU P0303719A HU P0303719 A2 HUP0303719 A2 HU P0303719A2
- Authority
- HU
- Hungary
- Prior art keywords
- mitoxantrone
- liposomal
- pharmaceutical composition
- amitoxantrone
- preparation
- Prior art date
Links
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001156 mitoxantrone Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Jelen találmány mitoxantron hatóanyag-tartalmú liposzómásgyógyszerkészítményekre, ezek előállítási eljárásaira és alkalmazásáravonatkozik. A jelen találmány szerinti gyógyszerkészítmények amitoxantron liposzómás összetételeit tartalmazzák, amelyekben aliposzóma a különféle semleges vagy töltéssel rendelkezőliposzómaképző vegyületekkel együtt egy olyan anyagot tartalmaz,amelyről ismert, hogy megköti a mitoxantront. Ilyen anyag például akardiolipin. A liposzómás készítmények előnyösen alkalmazhatók amitoxantrontól különböző másodlagos terápiás szerekkel együtt, példáulantineoplazmás, gombaellenes szerekkel, antibiotikumokkal stb. Atalálmány a gyógyszerkészítmény-összetétel terápiásan hatékonymennyiségének adagolásából álló eljárásokra is vonatkozik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24106900P | 2000-10-16 | 2000-10-16 | |
PCT/US2001/042757 WO2002032400A1 (en) | 2000-10-16 | 2001-10-16 | Liposomal formulation of mitoxantrone |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0303719A2 true HUP0303719A2 (hu) | 2004-03-01 |
Family
ID=22909113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303719A HUP0303719A2 (hu) | 2000-10-16 | 2001-10-16 | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra |
Country Status (15)
Country | Link |
---|---|
US (1) | US20030219476A1 (hu) |
EP (1) | EP1333811A4 (hu) |
JP (1) | JP2004511510A (hu) |
CN (1) | CN1469735A (hu) |
AU (1) | AU2002214649A1 (hu) |
BR (1) | BR0114713A (hu) |
CA (1) | CA2424345A1 (hu) |
CZ (1) | CZ20031262A3 (hu) |
EA (1) | EA200300473A1 (hu) |
HU (1) | HUP0303719A2 (hu) |
IL (1) | IL155291A0 (hu) |
MX (1) | MXPA03003401A (hu) |
NO (1) | NO20031623L (hu) |
WO (1) | WO2002032400A1 (hu) |
ZA (1) | ZA200302670B (hu) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262173B2 (en) | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
AU2001270385B2 (en) * | 2000-06-30 | 2006-05-25 | Talon Therapeutics, Inc. | Liposomal antineoplastic drugs and uses thereof |
ATE413164T1 (de) * | 2000-11-09 | 2008-11-15 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
WO2003018018A2 (en) * | 2001-08-24 | 2003-03-06 | Neopharm, Inc. | Vinorelbine compositions and methods of use |
JP2005508375A (ja) * | 2001-11-09 | 2005-03-31 | ネオファーム、インコーポレイティッド | Il−13を発現する腫瘍の選択的治療 |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
US20050153297A1 (en) * | 2002-05-29 | 2005-07-14 | Ateeq Ahmad | Method for determining oligonucleotide concentration |
AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
JP2006517594A (ja) * | 2003-02-11 | 2006-07-27 | ネオファーム、インコーポレイティッド | リポソーム製剤の製造方法 |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
US20060165744A1 (en) * | 2003-05-22 | 2006-07-27 | Neopharm, Inc | Combination liposomal formulations |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
EA200700626A1 (ru) * | 2004-09-15 | 2007-10-26 | Васоджен Айеленд Лимитед | Лечение множественного склероза |
JP4990786B2 (ja) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
CA2631872C (en) | 2005-12-08 | 2014-04-01 | Transave, Inc. | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
PL2076244T3 (pl) * | 2006-10-10 | 2017-05-31 | Jina Pharmaceuticals Inc. | Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie |
CA2669355C (en) | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
CN101209243B (zh) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
TWI583403B (zh) | 2009-06-04 | 2017-05-21 | 國立感染症研究所 | 黴漿菌感染症用疫苗 |
CN101773471B (zh) * | 2010-03-25 | 2012-07-11 | 天津大学 | 一种米托蒽醌纳米靶向缓释长循环脂质体及制备方法 |
EP2561353A4 (en) * | 2010-04-19 | 2013-08-28 | Univ North Carolina | PREDICTORS FOR PHARMACOKINETIC AND PHARMACODYNAMIC ARRANGEMENT OF VEHICLE MEDIATED AGENTS |
CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
SI2852391T1 (sl) | 2012-05-21 | 2022-04-29 | Insmed Incorporated | Sistemi za obravnavo pljučnih infekcij |
JP6419710B2 (ja) | 2012-11-20 | 2018-11-07 | スペクトラム ファーマシューティカルズ | 治療的使用のためのリポソーム封入ビンクリスチンの調製のための改良法 |
EP2925298B1 (en) | 2012-11-29 | 2019-05-29 | Insmed Incorporated | Stabilized vancomycin formulations |
EP3766501B1 (en) | 2014-05-15 | 2022-07-06 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
WO2019232417A1 (en) * | 2018-06-01 | 2019-12-05 | Washington University | Compounds and methods for the treatment of toxoplasma gondii infection |
CN110711178A (zh) * | 2018-07-11 | 2020-01-21 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
WO2021180184A1 (zh) * | 2020-03-12 | 2021-09-16 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体的用途 |
CN114601791B (zh) * | 2020-12-08 | 2023-09-19 | 成都倍特药业股份有限公司 | 一种盐酸米托蒽醌液体制剂及其制备方法 |
AU2021399438A1 (en) * | 2020-12-15 | 2023-07-06 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of mitoxantrone hydrochloride liposome |
CN115770288A (zh) * | 2021-09-07 | 2023-03-10 | 石药集团中奇制药技术(石家庄)有限公司 | 米托蒽醌脂质体、硼替佐米和***治疗多发性骨髓瘤的用途 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4197249A (en) * | 1977-08-15 | 1980-04-08 | American Cyanamid Company | 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof |
US4820738A (en) * | 1977-08-15 | 1989-04-11 | American Cyanamid Company | 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof |
US4428882A (en) * | 1979-05-29 | 1984-01-31 | American Cyanamid Company | 1-(Aminoalkylamino)-5,8-dihydroxy-4-substituted-anthraquinones |
US4376765A (en) * | 1980-03-31 | 1983-03-15 | Institut International De Pathologie Cellulaire Et Moleculaire | Medicaments, their preparation and compositions containing same |
DE3360633D1 (en) * | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
JPS60246400A (ja) * | 1984-05-22 | 1985-12-06 | Ajinomoto Co Inc | アントラサイクリン系化合物及び制ガン剤 |
IL76002A0 (en) * | 1984-08-03 | 1985-12-31 | Boehringer Biochemia Srl | Amino-anthracenediones-platinum complexes useful as anti-cancer compounds |
GB8508508D0 (en) * | 1985-04-01 | 1985-05-09 | Creighton A M | Pharmaceutical compositions |
EP0198765A3 (en) * | 1985-04-09 | 1987-10-21 | Georgetown University | Preparation of liposomes |
US4739046A (en) * | 1985-08-19 | 1988-04-19 | Luzio Nicholas R Di | Soluble phosphorylated glucan |
US5187167A (en) * | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
IN165717B (hu) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5716829A (en) * | 1987-01-15 | 1998-02-10 | Genetic Systems Corporation | Diagnostic test for Pseudomonas aeruginosa infections |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
US5000886A (en) * | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5744455A (en) * | 1988-01-27 | 1998-04-28 | New York University | Reduction of anthracycline-induced cardiotoxicity |
US5610180A (en) * | 1988-01-29 | 1997-03-11 | Virginia Commonwealth University | Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents |
CA1335348C (en) * | 1988-03-04 | 1995-04-25 | Yasuaki Ogawa | Liposome composition |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
CA2056435A1 (en) * | 1989-05-15 | 1990-11-16 | Thomas D. Madden | Accumulation of drugs into liposomes by a proton gradient |
GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
GB9017024D0 (en) * | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
EP0470569B1 (en) * | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
FI101678B1 (fi) * | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
JP2783680B2 (ja) * | 1991-01-11 | 1998-08-06 | ラボラトワール、グラクソ、ソシエテ、アノニム | アクリジン誘導体 |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
GB9108652D0 (en) * | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
US5399338A (en) * | 1991-05-01 | 1995-03-21 | University Of New Mexico | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy |
US5620971A (en) * | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
US6017900A (en) * | 1991-07-03 | 2000-01-25 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and nsaids |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
AU3737893A (en) * | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
ES2148223T3 (es) * | 1992-03-23 | 2000-10-16 | Univ Georgetown | Taxol encapsulado en liposomas y metodo para su uso. |
US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
US5301688A (en) * | 1992-08-07 | 1994-04-12 | Physion S.R.L. | Method for localization and therapy of occult bladder cancer |
WO1994005259A1 (en) * | 1992-09-02 | 1994-03-17 | Georgetown University | Method of encapsulating anthracycline glycosides in liposomes |
GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
FR2702656B1 (fr) * | 1993-03-18 | 1995-06-16 | Sanofi Elf | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs. |
US5378456A (en) * | 1993-03-25 | 1995-01-03 | American Cyanamid Company | Antitumor mitoxantrone polymeric compositions |
US5807549A (en) * | 1993-05-21 | 1998-09-15 | Research Corporation Technologies, Inc. | Lymphocyte chemoattractant factor and uses thereof |
EP0647450A1 (en) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
US5599712A (en) * | 1993-10-15 | 1997-02-04 | University Of Pittsburgh | Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy |
IN176897B (hu) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
GB9325330D0 (en) * | 1993-12-10 | 1994-02-16 | Univ Toronto | Fluorocyclodextrin drug delivery system |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
GB9402805D0 (en) * | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
US5618528A (en) * | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
US5730968A (en) * | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
US5604090A (en) * | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
US5716612A (en) * | 1994-09-07 | 1998-02-10 | Schering Corporation | Use of IL-4 for potentiation of chemotherapeutic agents |
US5602142A (en) * | 1994-12-21 | 1997-02-11 | Evanston Hospital Corporation | DNA-affinic hypoxia selective cytotoxins |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
GB9509888D0 (en) * | 1995-05-16 | 1995-07-12 | Pharmacia Spa | Terpenoidic derivatives useful as antitumour agents |
US5726184A (en) * | 1995-05-19 | 1998-03-10 | Vertex Pharmaceuticals Incorporated | Tetralin compounds with improved MDR activity |
US6200992B1 (en) * | 1995-06-07 | 2001-03-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
DE19538402A1 (de) * | 1995-10-14 | 1997-04-17 | Boehringer Mannheim Gmbh | Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel |
US5874412A (en) * | 1996-03-22 | 1999-02-23 | Priebe; Waldemar | Bis-anthracyclines with high activity against doxorubicin resistant tumors |
US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US6197295B1 (en) * | 1996-09-25 | 2001-03-06 | Viva America Marketing Corporation | Dietary supplementation with, and methods for administration of yeast-derived selenium product |
US6177404B1 (en) * | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
US6339069B1 (en) * | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US6207673B1 (en) * | 1997-03-12 | 2001-03-27 | The University Of North Carolina At Chapel Hill | Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
US6180666B1 (en) * | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
US6020316A (en) * | 1997-09-25 | 2000-02-01 | Lanks; Karl W. | Glutaraldehyde modified chemotherapeutic agents and methods of use thereof |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
JP2001526033A (ja) * | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | ヒトインターフェロン−イプシロンというi型インターフェロン |
US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
CA2334809A1 (en) * | 1998-06-05 | 1999-12-09 | Board Of Regents, The University Of Texas System | Texaphyrin conjugates and uses thereof |
US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
JP2002519335A (ja) * | 1998-06-26 | 2002-07-02 | クアナム メディカル コーポレイション | 再狭窄の予防のためのトポイソメラーゼインヒビター |
US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
US6174903B1 (en) * | 1998-12-28 | 2001-01-16 | Pfizer Inc. | Imidazolidin-4-one derivatives useful as anticancer agents |
US6200599B1 (en) * | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
AU3104301A (en) * | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
US20020004070A1 (en) * | 2000-02-24 | 2002-01-10 | Rudnic Edward M. | Antineoplastic product, use and formulation thereof |
US7405080B2 (en) * | 2000-03-23 | 2008-07-29 | Voellmy Richard W | Compositions and methods relating to prevention of chemotherapy-induced alopecia |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
WO2001085345A1 (en) * | 2000-05-10 | 2001-11-15 | Rtp Pharma Inc. | Media milling |
US6733764B2 (en) * | 2000-06-14 | 2004-05-11 | Alain Martin | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer |
US20020004511A1 (en) * | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
US6338859B1 (en) * | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
-
2001
- 2001-10-16 WO PCT/US2001/042757 patent/WO2002032400A1/en not_active Application Discontinuation
- 2001-10-16 CN CNA018174248A patent/CN1469735A/zh active Pending
- 2001-10-16 IL IL15529101A patent/IL155291A0/xx unknown
- 2001-10-16 AU AU2002214649A patent/AU2002214649A1/en not_active Abandoned
- 2001-10-16 EA EA200300473A patent/EA200300473A1/ru unknown
- 2001-10-16 MX MXPA03003401A patent/MXPA03003401A/es unknown
- 2001-10-16 EP EP01983203A patent/EP1333811A4/en not_active Withdrawn
- 2001-10-16 JP JP2002535638A patent/JP2004511510A/ja active Pending
- 2001-10-16 CA CA002424345A patent/CA2424345A1/en not_active Abandoned
- 2001-10-16 BR BR0114713-7A patent/BR0114713A/pt not_active Application Discontinuation
- 2001-10-16 HU HU0303719A patent/HUP0303719A2/hu unknown
- 2001-10-16 CZ CZ20031262A patent/CZ20031262A3/cs unknown
-
2003
- 2003-04-04 ZA ZA200302670A patent/ZA200302670B/en unknown
- 2003-04-09 NO NO20031623A patent/NO20031623L/no not_active Application Discontinuation
- 2003-04-14 US US10/413,061 patent/US20030219476A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200300473A1 (ru) | 2003-08-28 |
CN1469735A (zh) | 2004-01-21 |
AU2002214649A1 (en) | 2002-04-29 |
MXPA03003401A (es) | 2004-06-30 |
US20030219476A1 (en) | 2003-11-27 |
ZA200302670B (en) | 2004-07-05 |
NO20031623D0 (no) | 2003-04-09 |
IL155291A0 (en) | 2003-11-23 |
WO2002032400A1 (en) | 2002-04-25 |
CA2424345A1 (en) | 2002-04-25 |
JP2004511510A (ja) | 2004-04-15 |
EP1333811A1 (en) | 2003-08-13 |
BR0114713A (pt) | 2004-01-13 |
NO20031623L (no) | 2003-06-05 |
CZ20031262A3 (en) | 2004-03-17 |
EP1333811A4 (en) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303719A2 (hu) | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra | |
HUP0302319A2 (hu) | Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
ES2091441T3 (es) | Composicion farmaceutica. | |
BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
HUP0300826A2 (hu) | Egy epotilon-analóg polimorfjai, eljárás az elżállításukra és ezeket tartalmazó gyógyszerkészítmények | |
WO2003082853A8 (en) | New compounds | |
WO2004043363A3 (en) | Protein-stabilized liposomal formulations of pharmaceutical agents | |
HUP0101580A2 (hu) | Gélesedő gyógyászati készítmények | |
WO2001044271A3 (en) | Daptomycin analogs and their use as antibacterial agents | |
HUP0102337A2 (hu) | Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek felső légutakba és/vagy fülbe történő beadására szolgáló készítmények előállítására | |
HUP0302131A2 (hu) | Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények | |
AU4711296A (en) | Method for loading lipid vesicles | |
HUP0104255A2 (hu) | Inhalációra alkalmas gyógyászati készítmény | |
BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
NO20030897L (no) | Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer | |
SE0100569D0 (sv) | New compounds | |
AU2002214389A1 (en) | Pharmaceutical composition containing honey for the treatment of wounds | |
AU2108500A (en) | Galenic formulation containing biotin | |
HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
ATE489940T1 (de) | Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen | |
HUP0302036A2 (hu) | Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére | |
CA2420640A1 (en) | Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients | |
AP2002002572A0 (en) | Novel substituted pyrazol(4,3-e) diazepines, pharmaceutical compositions containing them, as medical products and processes for preparing them | |
WO2003037295A3 (en) | Micelle compositions containing pegylated phospholipids and a photosensitizer |